Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breakthrough Agreement On EU HTA Regulation “Falls Short”

Executive Summary

The European Parliament and EU Council have reached an agreement on taking forward proposals for greater cooperation on health technology assessments.

You may also be interested in...



European HTA Legislation Clears Final Hurdle

Risk of unpredictable system still real depending on how EU member states approach joint clinical assessments, warns industry.

Council of European Union Signs Off HTA Legislation

After years of wrangling, the legislative process for new regulation on greater cooperation on health technology appraisals across the EU has entered its final stages, with parliament expected to adopt the legislation soon.

New EU HTA Consortium Prepares To Launch

Two new groups have been formed in preparation for the application of the EU regulation on health technology assessment cooperation.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel